buspirone has been researched along with Alcohol Abuse in 36 studies
Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.
buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether females with a confirmed paternal history of alcoholism (FHP; n=14) were differentially sensitive to the mood and performance effects of alprazolam and buspirone compared with females without a first-degree family history of alcoholism (FHN; n=14)." | 9.09 | Increased sensitivity to alprazolam in females with a paternal history of alcoholism. ( Evans, SM; Fischman, MW; Levin, FR, 2000) |
| "Buspirone, a 5-HT1A agonist, has been shown to decrease the intake of ethanol when given as a single dose to rats with a psychological dependence induced according to our rat model of alcoholism." | 7.70 | Acute and long term effects of buspirone treatments on voluntary ethanol intake in a rat model of alcoholism. ( Hedlund, L; Wahlström, G, 1999) |
| "The author presents a case report of a 46-year-old man with generalized anxiety disorder and transvestic fetishism who responded to treatment with buspirone." | 7.67 | Buspirone hydrochloride in the treatment of transvestic fetishism. ( Fedoroff, JP, 1988) |
| "To determine whether females with a confirmed paternal history of alcoholism (FHP; n=14) were differentially sensitive to the mood and performance effects of alprazolam and buspirone compared with females without a first-degree family history of alcoholism (FHN; n=14)." | 5.09 | Increased sensitivity to alprazolam in females with a paternal history of alcoholism. ( Evans, SM; Fischman, MW; Levin, FR, 2000) |
| " Subjects were male veterans suffering from high levels of anxiety in addition to alcohol dependence who were randomly assigned to treatment with a placebo or buspirone." | 5.08 | Alcohol treatment: measurement of effectiveness by global outcome. ( Brown, JM; Malcolm, R; Randall, CL; Thevos, AK, 1996) |
| "The present study is a double-blind control trial of buspirone versus placebo in highly anxious alcoholics who recently completed inpatient detoxification for alcoholism." | 5.07 | A placebo-controlled trial of buspirone in anxious inpatient alcoholics. ( Anton, RF; Brady, K; Johnston, A; Malcolm, R; Randall, CL; Thevos, A, 1992) |
| " We investigated 51 dually diagnosed patients (generalized anxiety/alcohol abuse:dependence) in a randomized, double-blind, placebo-controlled trial of the serotonin partial agonist buspirone." | 5.07 | Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). ( Montague-Clouse, J; Tollefson, GD; Tollefson, SL, 1992) |
| " We investigated 51 dually diagnosed patients (generalized anxiety disorder with depressive features plus alcohol abuse/dependency) under a randomized, double-blind, placebo-controlled trial employing the 5-HT1A compound buspirone." | 5.07 | The association of buspirone and its metabolite 1-pyrimidinylpiperazine in the remission of comorbid anxiety with depressive features and alcohol dependency. ( Lancaster, SP; Montague-Clouse, J; Tollefson, GD, 1991) |
| "The five published controlled studies on the effects of buspirone in alcoholism treatment are reviewed." | 4.79 | Efficacy of buspirone in alcohol dependence: a review. ( Dongier, M; Malec, EA; Malec, TS, 1996) |
| "Buspirone, a 5-HT1A agonist, has been shown to decrease the intake of ethanol when given as a single dose to rats with a psychological dependence induced according to our rat model of alcoholism." | 3.70 | Acute and long term effects of buspirone treatments on voluntary ethanol intake in a rat model of alcoholism. ( Hedlund, L; Wahlström, G, 1999) |
| "The effect of buspirone, a drug with mainly 5-HT1A-agonist activity, on voluntary ethanol intake was tested in a rat model of alcoholism." | 3.69 | Buspirone as an inhibitor of voluntary ethanol intake in male rats. ( Hedlund, L; Wahlström, G, 1996) |
| "The author presents a case report of a 46-year-old man with generalized anxiety disorder and transvestic fetishism who responded to treatment with buspirone." | 3.67 | Buspirone hydrochloride in the treatment of transvestic fetishism. ( Fedoroff, JP, 1988) |
| "Buspirone therapy was associated with greater retention in the 12-week treatment trial, reduced anxiety, a slower return to heavy alcohol consumption, and fewer drinking days during the follow-up period." | 2.67 | Buspirone treatment of anxious alcoholics. A placebo-controlled trial. ( Babor, TF; Bohn, MJ; Brown, J; Burleson, JA; Del Boca, FK; Korner, P; Kranzler, HR, 1994) |
| "Buspirone treatment was also associated with a 57% decrease in DBI scores; statistical comparison of the DBI data with placebo was precluded by the high discontinuation rate in the placebo group." | 2.66 | Buspirone in the treatment of alcoholic patients. ( Bruno, F, 1989) |
| " The effects of intoxication, withdrawal, and chronic use on anxiety and need to be taken into account and the primary vs." | 2.38 | The treatment of anxiety in patients with alcoholism. ( Borg, L; Frances, RJ, 1993) |
| "Although essentially limited to alcohol abusers, clinical studies seem to support the preclinical findings that a number of 5-HT reuptake inhibitors decrease interest in and intake of alcohol in mild-moderate ethanol-dependent individuals." | 2.38 | Opportunities for treatment of psychoactive substance use disorders with serotonergic medications. ( Higgins, GA; Romach, MK; Sellers, EM; Tomkins, DM; Toneatto, T, 1991) |
| "Buspirone was without important effects on the high alcohol preferring rats." | 1.29 | Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference. ( Meert, TF, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (19.44) | 18.7374 |
| 1990's | 25 (69.44) | 18.2507 |
| 2000's | 3 (8.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Ko, YE | 1 |
| Hwa, LS | 1 |
| Kranzler, HR | 4 |
| Burleson, JA | 1 |
| Del Boca, FK | 2 |
| Babor, TF | 1 |
| Korner, P | 1 |
| Brown, J | 2 |
| Bohn, MJ | 1 |
| de Oliveira, IR | 1 |
| da Rocha, FP | 1 |
| Pereira, EL | 1 |
| Miranda, Ade A | 1 |
| Ribeiro, MG | 1 |
| Melo, A | 1 |
| Frances, RJ | 1 |
| Borg, L | 1 |
| Meert, TF | 1 |
| Malec, E | 1 |
| Malec, T | 1 |
| Gagné, MA | 1 |
| Dongier, M | 2 |
| Hedlund, L | 2 |
| Wahlström, G | 2 |
| Thevos, AK | 1 |
| Brown, JM | 1 |
| Malcolm, R | 3 |
| Randall, CL | 2 |
| Malec, TS | 1 |
| Malec, EA | 1 |
| Korner, PF | 1 |
| Ciraulo, DA | 1 |
| Barnhill, JG | 1 |
| Ciraulo, AM | 1 |
| Sarid-Segal, O | 1 |
| Knapp, C | 1 |
| Greenblatt, DJ | 1 |
| Shader, RI | 1 |
| Sprenger, D | 1 |
| Moncrieff, J | 1 |
| Drummond, DC | 1 |
| Kravitz, HM | 2 |
| Fawcett, J | 2 |
| McGuire, M | 2 |
| Kravitz, GS | 1 |
| Whitney, M | 2 |
| George, DT | 1 |
| Rawlings, R | 1 |
| Eckardt, MJ | 1 |
| Phillips, MJ | 1 |
| Shoaf, SE | 1 |
| Linnoila, M | 1 |
| Easton, M | 1 |
| Ross, J | 1 |
| Pisani, V | 1 |
| Fogg, LF | 1 |
| Clark, D | 1 |
| Kravitz, G | 1 |
| Javaid, J | 1 |
| Teas, G | 1 |
| Evans, SM | 1 |
| Levin, FR | 1 |
| Fischman, MW | 1 |
| Myrick, H | 1 |
| Brady, KT | 1 |
| Anton, RF | 1 |
| Johnston, A | 1 |
| Brady, K | 1 |
| Thevos, A | 1 |
| Overstreet, DH | 2 |
| Rezvani, AH | 2 |
| Janowsky, DS | 2 |
| Tollefson, GD | 3 |
| Montague-Clouse, J | 2 |
| Tollefson, SL | 1 |
| Sellers, EM | 1 |
| Higgins, GA | 1 |
| Tomkins, DM | 1 |
| Romach, MK | 1 |
| Toneatto, T | 1 |
| Iruela, LM | 1 |
| Ibañez-Rojo, V | 1 |
| Caballero, L | 1 |
| Baca, E | 1 |
| Lancaster, SP | 1 |
| McIvor, R | 1 |
| Sinanan, K | 1 |
| Wang, RI | 1 |
| Tiuseco, D | 1 |
| Roh, BL | 1 |
| Cho, JK | 1 |
| Kochar, C | 1 |
| Bruno, F | 1 |
| Sáiz, J | 1 |
| Meyer, RE | 2 |
| Fedoroff, JP | 1 |
| Griffith, JD | 1 |
| Jasinski, DR | 1 |
| Casten, GP | 1 |
| McKinney, GR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence[NCT01549652] | 133 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -0.44 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.68 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.59 |
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in BDIS (Ondansetron) | Change in BDIS (Placebo) | |
| Prevention of Physical Dependence | -0.6 | 0.2 |
"Originally developed by Handelsman, the Objective Opioid Withdrawal Scale (OOWS) score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The minimum score of 0 means the patient is not showing any signs of opioid withdrawal. The maximum score of 13 signifies all signs of opioid withdrawal to the largest extent possible.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If deemed necessary by the clinician, participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 3.6 | 3.6 |
"Originally developed by Handelsman, the OOWS score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The maximum score is 13 and suggests the patient is showing all signs of opioid withdrawal to the largest extent possible. The minimum score of 0 suggests the patient is not showing any signs of opioid withdrawal.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Physical Dependence | 4.5 | 4.2 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in VAS Score (Ondansetron) | Change in VAS Score (Placebo) | |
| Prevention of Physical Dependence | -2.9 | -2.8 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in RMDI (Ondansetron) | Change in RMDI (Placebo) | |
| Prevention of Physical Dependence | -4.6 | -2.0 |
The Subjective Opioid Withdrawal Score (SOWS) score is calculated as the sum of 16 subjective patient-reported symptom scores rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 12.5 | 12.2 |
The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Physical Dependence | 16.4 | 12.0 |
Profile of Mood States (POMS) is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS Score (Ondansetron) | Change in POMS Score (Placebo) | |
| Prevention of Opioid Withdrawal | 29.3 | 28.3 |
(Profile of Mood States) POMS is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS (Ondansetron) | Change in POMS (Placebo) | |
| Prevention of Physical Dependence | 36.1 | 29.2 |
7 reviews available for buspirone and Alcohol Abuse
| Article | Year |
|---|---|
The treatment of anxiety in patients with alcoholism.
Topics: Alcoholism; Anxiety Disorders; Benzodiazepines; Buspirone; Combined Modality Therapy; Comorbidity; D | 1993 |
Evaluation and treatment of anxiety symptoms and disorders in alcoholics.
Topics: Alcohol Drinking; Alcoholism; Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Buspirone; Clinical T | 1996 |
Efficacy of buspirone in alcohol dependence: a review.
Topics: Alcoholism; Anti-Anxiety Agents; Anxiety Disorders; Buspirone; Clinical Trials as Topic; Comorbidity | 1996 |
New developments in the pharmacotherapy of alcohol dependence.
Topics: Acamprosate; Adjuvants, Anesthesia; Alcohol Deterrents; Alcoholism; Anticonvulsants; Buspirone; Carb | 2001 |
Opportunities for treatment of psychoactive substance use disorders with serotonergic medications.
Topics: Alcoholism; Animals; Buspirone; Comorbidity; Humans; Mental Disorders; Psychotropic Drugs; Rats; Rec | 1991 |
Anxiety and alcoholism: a serotonin link.
Topics: Alcoholism; Animals; Anxiety Disorders; Brain; Buspirone; Disease Models, Animal; Humans; Personalit | 1991 |
[Buspirone in alcoholic patients].
Topics: Alcoholism; Buspirone; Drug Interactions; Ethanol; Humans | 1989 |
15 trials available for buspirone and Alcohol Abuse
| Article | Year |
|---|---|
Buspirone treatment of anxious alcoholics. A placebo-controlled trial.
Topics: Adult; Alcohol Drinking; Alcoholism; Anxiety Disorders; Buspirone; Cognitive Behavioral Therapy; Com | 1994 |
Buspirone in the treatment of alcohol dependence: a placebo-controlled trial.
Topics: Adult; Alcoholism; Anti-Anxiety Agents; Anxiety Disorders; Buspirone; Comorbidity; Double-Blind Meth | 1996 |
Alcohol treatment: measurement of effectiveness by global outcome.
Topics: Adult; Aged; Alcoholism; Anxiety; Buspirone; Hospitals, Veterans; Humans; Male; Middle Aged; Random | 1996 |
Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer.
Topics: Alcoholism; Anti-Anxiety Agents; Buspirone; Dose-Response Relationship, Drug; Double-Blind Method; F | 1996 |
Alterations in pharmacodynamics of anxiolytics in abstinent alcoholic men: subjective responses, abuse liability, and electroencephalographic effects of alprazolam, diazepam, and buspirone.
Topics: Adult; Affect; Alcoholism; Alprazolam; Anti-Anxiety Agents; Buspirone; Diazepam; Electrocardiography | 1997 |
Treatment attrition among alcohol-dependent men: is it related to novelty seeking personality traits?
Topics: Adult; Alcoholism; Buspirone; Double-Blind Method; Humans; Lithium; Male; Multivariate Analysis; Pat | 1999 |
Buspirone treatment of alcoholism: age of onset, and cerebrospinal fluid 5-hydroxyindolacetic acid and homovanillic acid concentrations, but not medication treatment, predict return to drinking.
Topics: Adult; Age of Onset; Alcoholism; Anti-Anxiety Agents; Buspirone; Double-Blind Method; Homovanillic A | 1999 |
Pharmacological treatments for alcoholism: revisiting lithium and considering buspirone.
Topics: Adult; Alcoholism; Anti-Anxiety Agents; Antimanic Agents; Buspirone; Double-Blind Method; Humans; Li | 2000 |
Increased sensitivity to alprazolam in females with a paternal history of alcoholism.
Topics: Affect; Alcoholism; Alprazolam; Analysis of Variance; Anti-Anxiety Agents; Buspirone; Chi-Square Dis | 2000 |
A placebo-controlled trial of buspirone in anxious inpatient alcoholics.
Topics: Adult; Aftercare; Aged; Alcohol Drinking; Alcoholism; Anxiety Disorders; Buspirone; Dose-Response Re | 1992 |
Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone).
Topics: Adult; Alcoholism; Analysis of Variance; Anxiety Disorders; Buspirone; Double-Blind Method; Female; | 1992 |
The association of buspirone and its metabolite 1-pyrimidinylpiperazine in the remission of comorbid anxiety with depressive features and alcohol dependency.
Topics: Alcoholism; Anxiety Disorders; Buspirone; Depressive Disorder; Double-Blind Method; Humans | 1991 |
Buspirone in the treatment of alcoholic patients.
Topics: Adult; Alcohol Drinking; Alcoholism; Buspirone; Clinical Trials as Topic; Dose-Response Relationship | 1989 |
An open trial of buspirone in alcoholics.
Topics: Adult; Alcoholism; Buspirone; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Male | 1989 |
Investigation of the abuse liability of buspirone in alcohol-dependent patients.
Topics: Administration, Oral; Adult; Alcoholism; Appetite; Buspirone; Diazepam; Euphoria; Humans; Male; Midd | 1986 |
14 other studies available for buspirone and Alcohol Abuse
| Article | Year |
|---|---|
Serotonin regulation of intermittent and continuous alcohol drinking in male and female C57BL/6J mice with systemic SB242084 and buspirone.
Topics: Alcohol Drinking; Alcoholism; Animals; Buspirone; Ethanol; Female; Male; Mice; Mice, Inbred C57BL; S | 2023 |
Combined carbamazepine-buspirone treatment of alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Buspirone; Carbamazepine; Drug Administration Schedule; Drug Th | 1993 |
Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference.
Topics: Alcohol Drinking; Alcoholism; Animals; Buspirone; Chlordiazepoxide; Citalopram; Dose-Response Relati | 1993 |
Buspirone as an inhibitor of voluntary ethanol intake in male rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Anti-Anxiety Agents; Brain; Buspirone; Dose-Response Relation | 1996 |
Buspirone augmentation of a selective serotonin reuptake inhibitor: efficacy in two depressed patients with comorbid anxiety and type I alcohol dependence.
Topics: 1-Naphthylamine; Adult; Alcoholism; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; B | 1997 |
New drug treatments for alcohol problems: a critical appraisal.
Topics: Acamprosate; Alcoholism; Anti-Anxiety Agents; Buspirone; Dopamine Antagonists; Humans; Naltrexone; N | 1997 |
Acute and long term effects of buspirone treatments on voluntary ethanol intake in a rat model of alcoholism.
Topics: Alcohol Drinking; Alcoholism; Animals; Behavior, Animal; Buspirone; Disease Models, Animal; Dose-Res | 1999 |
Genetic animal models of depression and ethanol preference provide support for cholinergic and serotonergic involvement in depression and alcoholism.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Alcohol Drinking; Alcoholism; Animals; Arousal; Avoidance Le | 1992 |
Buspirone-induced mania: possible interaction with disulfiram.
Topics: Alcoholism; Bipolar Disorder; Buspirone; Disulfiram; Drug Therapy, Combination; Humans | 1991 |
Drug-induced reductions in ethanol intake in alcohol preferring and Fawn-Hooded rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Buspirone; Drinking Behavior; Ethanol; Feeding Behavior; Fluo | 1991 |
Buspirone-induced mania.
Topics: Adult; Alcoholism; Anxiety Disorders; Bipolar Disorder; Buspirone; Ethanol; Humans; Male | 1991 |
Can buspirone substitute for benzodiazepines in all anxious patients?
Topics: Adult; Alcoholism; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Buspirone; Humans; Male; | 1989 |
Anxiolytics and the alcoholic patient.
Topics: Alcohol Drinking; Alcoholism; Anti-Anxiety Agents; Arousal; Benzodiazepines; Brain; Buspirone; Drug | 1986 |
Buspirone hydrochloride in the treatment of transvestic fetishism.
Topics: Alcoholism; Anxiety Disorders; Buspirone; Fetishism, Psychiatric; Humans; Male; Middle Aged; Paraphi | 1988 |